NSFMF yields 3.52% · JNJ yields 2.13%● Live data
📍 NSFMF pulled ahead of the other in Year 1
Combined, NSFMF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NSFMF + JNJ for your $10,000?
Nisshin Seifun Group Inc. engages in the flour milling, processed foods, health foods, biotechnology, pet foods, engineering, and mesh cloth businesses in Japan and internationally. The company manufactures and sells wheat flour, bran, ready-made, and other food-related items; pasta, pasta sauces, premixes, flour for consumer use, heat-and-serve products, dried noodles, and chilled and frozen food products under the NISSHIN, MA?MA, AO-NO-DOKUTSU, and DE CECCO brands; deli foods under the INITIO brand; and health foods, active pharmaceutical ingredients, and pharmaceutical products. It also manufactures and sells pet food for dogs and cats under the JP Style brand; designs and manages manufacturing and processing facilities for grains, food materials, and chemicals; and sells powder processing related equipment. In addition, the company manufactures and sells yeast and other food ingredients, ingredients for diagnostic drugs, and drugs for research; materials for screen-printing, mesh products for industrial use, electronic components, and plastic molding; and deli dishes. Nisshin Seifun Group Inc. was founded in 1900 and is headquartered in Tokyo, Japan.
Full NSFMF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.